Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The small airways of the lung include the terminal and respiratory bronchioles and, in some definitions, the alveolar ducts. These structures have diameters generally less than 2 mm and lack supporting cartilage and submucosal glands[3][5]. Their main functions are conduction of air to the alveoli (where gas exchange occurs), humidification and cleaning via mucociliary clearance, and regulation of airway resistance through smooth muscle contraction[1][3][5]. Small airway dysfunction is implicated in several pulmonary diseases, including asthma, chronic obstructive pulmonary disease (COPD), and bronchiolitis, and is a key site of disease pathology and therapeutic intervention. Drugs such as inhaled corticosteroids, bronchodilators, and mucolytics may be optimized to reach the small airways, although the small airways themselves are not molecular targets but anatomical locations for the drug's site of action.
Local anti-inflammatory action (corticosteroids); Bronchodilation (β2-agonists, anticholinergics); Mucolytic effects (expectorants, though less direct)
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Small airway of the lung.